Navigation Links
Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
Date:1/24/2011

74; (Epoetin alfa) and ENBREL recalls.  These increases were partially offset by lower excess capacity charges and lower royalties, primarily for ENBREL.Research & Development (R&D) expenses decreased 5 percent to $825 million in the fourth quarter of 2010 versus $864 million in the fourth quarter of 2009.  This decrease was driven primarily by the $60 million licensing fee payment in the fourth quarter of 2009 associated with the Array BioPharma agreement.  This decrease in licensing fees was partially offset by lower cost recoveries associated with ongoing collaborations and higher staff related costs in 2010.For the year, R&D expenses were $2,773 million in 2010 versus $2,739 million in 2009, an increase of 1 percent.  The increase was driven primarily by lower cost recoveries associated with ongoing collaborations and higher staff related costs in 2010.  This was largely offset by lower licensing fees, principally associated with payments made in 2009 under the Cytokinetics and Array BioPharma agreements, and reduced denosumab clinical trial expenses in 2010.Selling, General & Administrative (SG&A) expenses declined slightly to $1,142 million in the fourth quarter of 2010 versus $1,159 million in the fourth quarter of 2009.For 2010, SG&A expenses increased 5 percent to $3,925 million versus $3,737 million in 2009.  This increase was due primarily to higher staff related costs, higher promotional costs for Prolia and other marketed products, and higher litigation expenses.ENBREL profit share expenses were $319 million and $1,184 million and $308 million and $1,163 million for the three and twelve months ended Dec. 31, 2010 and 2009, respectively.The adjusted tax rate for the fourth quarter of 2010 was 15.5 percent compared to 15.9 percent for the fourth quarter of 2009.  The decrease was due primarily to the full year benefit of the federal R&D credit recognized in the fourth quarter of
'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. PLC Systems Reports Fourth Quarter 2007 Results
5. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
9. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Introduction of new ... tools for radiosurgery/SBRT   The "Elements" ... enhancing the workflow for difficult to treat indications ... - comes full circle with the introduction of ... Elements enable on-the-fly generation of consistent treatment plans ...
(Date:4/24/2015)... Hi-Tech Pharmaceuticals refutes the results from ... of reliable scientific principles and methods and therefore ... of adulteration. The FDA is resting its very, ... misguided hope, that Methylphenylethylamine is not found in ... multiple other studies and cannot be relied on ...
(Date:4/24/2015)... , April 24, 2015 Hospira, ... in the development of biosimilar therapies, spoke about the ... at the European Generics Association (EGA) annual European Biosimilars ... The company also announced the publication of a ... to achieving the full promise of biosimilars." ...
Breaking Medicine Technology:Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7
(Date:4/25/2015)... 2015 The URO CENTER of NEW YORK ... chosen by the New York Academy of Medicine to receive ... the field of Urology. , Dr. Ferdinand Valentine, born in ... diseases. He was a man of rare and attractive ... Not only did he devote his life to his ...
(Date:4/24/2015)... Constellations Recovery celebrates the opening of ... Just 35 miles from New York City, Constellations Recovery ... life while recovering from addiction. The Open House, which ... therapists, doctors and treatment centers to see the residence, ... opportunities offered by Constellations Recovery.,  , The newly opened ...
(Date:4/24/2015)... April 24, 2015 The Fastest Fat Loss ... their great success of the Xtreme Fat Loss Diet, has ... The fat loss blueprint that claims to help one lose ... of HealthyandFitZone.com's Stan Stevenson, prompting an investigative review. , "Our ... the creators spent years researching and experimenting with these methods ...
(Date:4/24/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining how ... citizens . , Senior citizens may be considered ... they cannot find affordable coverage. By comparing online auto ... coverage for their cars at the best prices. ... provides free leads from various agencies that are in ...
(Date:4/24/2015)... “Kind,” “selfless,” “the voice of reason” and ... Weiner described pediatric oncology nurse Laura Vasquez of Children’s ... during her five-year battle with a malignant brain tumor. ... and numerous experimental treatments, Vasquez continued caring for Alexa, ... was not in the hospital and even sitting vigil ...
Breaking Medicine News(10 mins):Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2Health News:Low Cost Auto Insurance Quotes for Senior Citizens 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4
... New web-based research has quantified the attractiveness of the ... features of one woman into 243 variations with differing ... widths. Then more than 34,000 people judged the attractiveness ... the same in all of the photos, researchers found ...
... Old Republic International Corporation (NYSE: ORI ... the payment of the regular quarterly cash dividend of 17 ... March 13, 2009 to shareholders of record on March 4, ... rate initially approved for the second quarter of 2008. ...
... as Asian AffiliateNEW YORK and SINGAPORE, Feb. 26 ... prevention services, has signed an affiliation agreement with ... group based in Singapore and a subsidiary of ... medicine programs throughout Asia. Under the agreement, ParkwayHealth ...
... 274 adults with intellectual disabilities currently receiving funding ... , Washington, DC(February 23, 2009)The Supports Intensity ... for people with intellectual disability based on individual ... tool, unlike adaptive behavior instruments or other measures ...
... at the UCSF-Gladstone Institute for Virology and Immunology Center ... development of the next generation of HIV/AIDS researchers and ... published in the American Journal for Public Health ... of the AJPH website, the program focuses on overcoming ...
... Abbott ( NYSE: ABT ),today announced that it has ... now a wholly owned subsidiary of Abbott and has been,renamed ... acquisition of AMO enhances and strengthens Abbott,s diverse mix of,medical ... large and,growing eye care market. Abbott Medical Optics holds ...
Cached Medicine News:Health News:Plastic and reconstructive surgery ... in brief 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 3Health News:Supports Intensity Scale is effective for identifying needs in people with intellectual disability 2Health News:Effective mentoring critical to HIV/AIDS research efforts 2Health News:Abbott Completes Acquisition of Advanced Medical Optics 2